Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 17;41:326. doi: 10.1186/s13046-022-02525-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Low-doses chemotherapeutic drugs promote immune cell recruitment and activation of CD8⁺ T cells and NK cells in 975A2 tumors. A Schematic representation of the drug treatment and timing of tumor immune infiltrate analysis. B Tumor growth of 975A2 injected subcutaneously in C57BL/6 mice treated as indicated. Significance at day 7 after the start of treatment (Mann Whitney test). C Weight of explanted tumors at 7 days after the start of treatment. D, E Flow-cytometry analysis of immune content of 975A2 tumors treated 1 day (D) and 7 days (E). F, G Flow-cytometry analysis of IFNγ expression of tumor-infiltrating CD8⁺ T cells (F) and NK cells (G) in 7 day-treated 975A2 tumors. Levels of significance for comparison between samples were determined by ANOVA. CTR, vehicle control; CDDP, cisplatin; DX, doxorubicin; IRI, irinotecan; MTX, mitoxantrone; OXP, oxaliplatin; VINC, vincristine. Statistically significant P values are shown